We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Pfizer reported a strong sales performance for its antifungal drug Cresemba in the Asia Pacific and China, thanks to a ...

Pfizer Inc. closed 26.70% short of its 52-week high of $31.54, which the company achieved on July 30th.

Investing in stocks based on valuation metrics is considered a smart strategy. The price-to-earnings (P/E) ratio is often the go-to metric due to its simplicity and ease of use. However, the ...

A volatile stock market represents an ideal opportunity for long-term investors to pounce.

Pfizer’s stock has dropped 25% from its recent high, raising questions about whether it's a buy at $23. Pipeline failures and ...

Despite Pfizer management's cost-cutting and a large drug pipeline, revenue growth remains uncertain. Click here to read an ...

PFE stock offers high dividend yields supported by cost optimizations and R&D. Discover its potential amid COVID-19 sales ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.